Choroidal neovascularization: New dynamics of the VEGF signaling system

Olaf Strauss, Michael E. Boulton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Choroidal neovascularization (CNV) is the most severe complication in age-related macular degeneration. VEGF-A has been identified as the major angiogenic factor in CNV. Intraocular injections of substances that trap free VEGF-A represent the first intervention leading to vision improvement. New data imply a refinement by considering the Janus-like differential signaling at the VEGF receptor-1 leading to either pro- or antiangiogenic effects of VEGF-A to exploit possible antiangiogenic effects. Furthermore, the isoform VEGF-C appears to function synergistically with VEGF-A at endothelial cells and the retinal pigment epithelium. Thus, while the new therapies for CNV provide proof of principle for interventions at the VEGF signaling system, our recent discoveries regarding the dynamics of VEGF signaling provide new opportunities for more efficient approaches.

Original languageEnglish (US)
Pages (from-to)551-556
Number of pages6
JournalExpert Review of Ophthalmology
Volume2
Issue number4
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Endothelial cells
Pigments
Intraocular Injections
Vascular Endothelial Growth Factor C
Vascular Endothelial Growth Factor Receptor
Retinal Pigment Epithelium
Angiogenesis Inducing Agents
Macular Degeneration
Protein Isoforms
Endothelial Cells

Keywords

  • age-related macular degeneration
  • antiangiogenic effects
  • choroidal neovascularization
  • proangiogenic effects
  • therapy
  • VEGF
  • VEGF receptor-1

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

Choroidal neovascularization : New dynamics of the VEGF signaling system. / Strauss, Olaf; Boulton, Michael E.

In: Expert Review of Ophthalmology, Vol. 2, No. 4, 01.08.2007, p. 551-556.

Research output: Contribution to journalArticle

Strauss, Olaf ; Boulton, Michael E. / Choroidal neovascularization : New dynamics of the VEGF signaling system. In: Expert Review of Ophthalmology. 2007 ; Vol. 2, No. 4. pp. 551-556.
@article{ce1fa56f918e4c6f92a30e4b8dbf0325,
title = "Choroidal neovascularization: New dynamics of the VEGF signaling system",
abstract = "Choroidal neovascularization (CNV) is the most severe complication in age-related macular degeneration. VEGF-A has been identified as the major angiogenic factor in CNV. Intraocular injections of substances that trap free VEGF-A represent the first intervention leading to vision improvement. New data imply a refinement by considering the Janus-like differential signaling at the VEGF receptor-1 leading to either pro- or antiangiogenic effects of VEGF-A to exploit possible antiangiogenic effects. Furthermore, the isoform VEGF-C appears to function synergistically with VEGF-A at endothelial cells and the retinal pigment epithelium. Thus, while the new therapies for CNV provide proof of principle for interventions at the VEGF signaling system, our recent discoveries regarding the dynamics of VEGF signaling provide new opportunities for more efficient approaches.",
keywords = "age-related macular degeneration, antiangiogenic effects, choroidal neovascularization, proangiogenic effects, therapy, VEGF, VEGF receptor-1",
author = "Olaf Strauss and Boulton, {Michael E.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1586/17469899.2.4.551",
language = "English (US)",
volume = "2",
pages = "551--556",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Choroidal neovascularization

T2 - New dynamics of the VEGF signaling system

AU - Strauss, Olaf

AU - Boulton, Michael E.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Choroidal neovascularization (CNV) is the most severe complication in age-related macular degeneration. VEGF-A has been identified as the major angiogenic factor in CNV. Intraocular injections of substances that trap free VEGF-A represent the first intervention leading to vision improvement. New data imply a refinement by considering the Janus-like differential signaling at the VEGF receptor-1 leading to either pro- or antiangiogenic effects of VEGF-A to exploit possible antiangiogenic effects. Furthermore, the isoform VEGF-C appears to function synergistically with VEGF-A at endothelial cells and the retinal pigment epithelium. Thus, while the new therapies for CNV provide proof of principle for interventions at the VEGF signaling system, our recent discoveries regarding the dynamics of VEGF signaling provide new opportunities for more efficient approaches.

AB - Choroidal neovascularization (CNV) is the most severe complication in age-related macular degeneration. VEGF-A has been identified as the major angiogenic factor in CNV. Intraocular injections of substances that trap free VEGF-A represent the first intervention leading to vision improvement. New data imply a refinement by considering the Janus-like differential signaling at the VEGF receptor-1 leading to either pro- or antiangiogenic effects of VEGF-A to exploit possible antiangiogenic effects. Furthermore, the isoform VEGF-C appears to function synergistically with VEGF-A at endothelial cells and the retinal pigment epithelium. Thus, while the new therapies for CNV provide proof of principle for interventions at the VEGF signaling system, our recent discoveries regarding the dynamics of VEGF signaling provide new opportunities for more efficient approaches.

KW - age-related macular degeneration

KW - antiangiogenic effects

KW - choroidal neovascularization

KW - proangiogenic effects

KW - therapy

KW - VEGF

KW - VEGF receptor-1

UR - http://www.scopus.com/inward/record.url?scp=79955988397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955988397&partnerID=8YFLogxK

U2 - 10.1586/17469899.2.4.551

DO - 10.1586/17469899.2.4.551

M3 - Article

AN - SCOPUS:79955988397

VL - 2

SP - 551

EP - 556

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 4

ER -